Every Form 4 that Spruce Biosciences, Inc. (SPRB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SPRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRB filings page.
Quartel Adrian W reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences’ Chief Medical Officer Adrian W. Quartel reported a grant of 13,000 Restricted Stock Units (RSUs) on July 27, 2026. Each RSU represents one share of common stock. The award vests 25% on June 15 of each year from 2027 through 2030, subject to his continuous service, resulting in direct holdings of 13,000 RSUs.
SPRUCE BIOSCIENCES, INC. Chief Executive Officer Javier B. Szwarcberg acquired 266 shares of common stock at $4.5305 per share through the company’s 2020 Employee Stock Purchase Plan. This grant increased his direct holdings to 19,270 shares, reflecting routine compensation-related share accumulation rather than an open-market trade.
Spruce Biosciences director Daniel K. Spiegelman received a grant of stock options for 1,700 shares of Common Stock. The options have an exercise price of 52.7000 per share and expire on May 20, 2036. Following this grant, he holds 1,700 derivative securities directly.
The options vest on the first anniversary of the grant date, with full vesting no later than the company’s 2027 annual stockholder meeting, subject to his continuous service under the 2020 Equity Incentive Plan. The award will also vest in full upon a Change in Control as defined in that plan.
Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.
SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.
Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.
The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.
Spruce Biosciences director Keli Walbert received a new stock option grant. The Form 4 shows an award of 1,700 stock options for common stock at an exercise price of $52.70 per share, with 1,700 derivative securities held after the transaction.
The options vest on the first anniversary of the grant date and will in any case be fully vested by the company’s 2027 annual stockholder meeting, subject to continuous service. They also vest in full upon a change in control. This is a compensation-related grant, not an open-market purchase or sale.
Hooks Corwin Dale reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences, Inc. reported that Chief Commercial Officer Corwin Dale Hooks received a grant of 11,000 Restricted Stock Units. Each RSU represents a contingent right to one share of common stock. The units vest in four equal 25% installments each March 15 from 2027 through 2030, conditioned on continued service.
Spruce Biosciences interim Chief Medical Officer Douglas Kirk Ways, who also serves as a director, reported new equity awards and option changes. On December 11, 2025, he was granted 5,000 restricted stock units (RSUs), each representing one share of common stock. According to the vesting terms, 25% (1,250 RSUs) vested on grant and converted into 1,250 shares of common stock at a price of $0, with the remaining RSUs scheduled to vest in three equal 25% installments on December 15, 2026, 2027 and 2028, subject to continuous service.
The filing also details a one-time stock option repricing effective December 11, 2025. Options with exercise prices of $106.09 per share or greater held by eligible employees and directors were amended so their exercise price is $104.13 per share, based on the 30‑day trailing volume‑weighted average price. The options remain fully vested or on their prior vesting schedules, share counts and expiration dates, and if exercised within a one‑year retention period the original higher exercise price must be paid.
Spruce Biosciences president and CFO Samir Gharib updated his share holdings following restricted stock unit (RSU) vesting. On December 15, 2025, 496 RSUs from a December 5, 2022 grant vested, with 178 shares of common stock withheld to cover taxes, resulting in a net issuance of 318 shares. The same day, 513 RSUs from a December 14, 2023 grant vested, with 184 shares withheld for taxes, resulting in a net issuance of 329 shares.
These transactions were reported as RSU conversions at an exercise price of $0, followed by share disposals coded as tax withholdings at $80.67 per share. After the reported transactions, Gharib directly beneficially owned 8,263 shares of Spruce Biosciences common stock.
Spruce Biosciences, Inc. chief executive officer and director reported multiple equity transactions. On December 15, 2025, 1,480 previously granted restricted stock units (RSUs) vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 common shares. On the same date, 1,196 additional RSUs vested, with 608 shares withheld for taxes and a net issuance of 588 shares.
Separately, effective December 11, 2025, 1,666 employee stock options with an original exercise price of $344.25 per share were replaced by 1,666 options with a reduced exercise price of $104.13 per share, reflecting a one-time option repricing based on the 30‑day volume‑weighted average price. If a repriced option is exercised before the end of a one‑year retention period, the holder must pay the original exercise price.
Spruce Biosciences, Inc. reported transactions by a director involving existing stock options after a 75-for-1 reverse stock split effective August 4, 2025. The reverse split combined every seventy-five shares of common stock into one share, and each option to purchase 75 shares became an option to purchase one share, with exercise prices multiplied by seventy-five.
On December 11, 2025, the company implemented a one-time stock option repricing for options with exercise prices of $106.09 per share or higher, held by employees and directors who remained in continuous service on that date. The exercise price of affected options was amended to $104.13 per share, equal to the 30-day trailing volume-weighted average price of the common stock on the Nasdaq Capital Market. The options are fully vested and exercisable, and if an optionholder exercises within a one-year retention period, they must pay the original exercise price. Vesting schedules, expiration dates, and the number of underlying shares were not changed.
Spruce Biosciences, Inc. reported Form 4 transactions for its executive chairman and director reflecting a one-time stock option repricing effective December 11, 2025. Options with exercise prices of $106.09 per share or greater were amended so the exercise price is now $104.13 per share, equal to the thirty-day trailing volume-weighted average price of the common stock on the Nasdaq Capital Market on the repricing date.
Most of the affected options are fully vested and exercisable, while one grant vests in 1/48th monthly installments from December 16, 2021. No changes were made to vesting schedules, expiration dates, or the number of shares underlying the repriced options. If a repriced option is exercised before the end of a one-year retention period, the holder must pay the original higher exercise price. Earlier, effective August 4, 2025, the company completed a reverse stock split in which every seventy-five shares of common stock, and the corresponding stock options, were combined into one and the option exercise prices were multiplied by seventy-five.
Spruce Biosciences insider Samir Gharib, President and CFO, reported changes to his stock options following a one-time option repricing effective December 11, 2025. The repricing applies to options with exercise prices of $106.09 per share or higher held by employees and directors who remained in continuous service as of that date.
Under this program, the exercise price of the affected options was amended to $104.13 per share, which equals the thirty-day trailing volume-weighted average price of Spruce Biosciences common stock on the Nasdaq Capital Market on the repricing date. If an optionholder exercises a repriced option before the end of a one-year retention period, they must still pay the original higher exercise price per share.
The repricing did not change vesting schedules, expiration dates, or the number of shares underlying the options. Certain grants for Gharib continue to vest in equal monthly installments of 1/48th of the shares from December 16, 2021 and January 3, 2022, conditioned on his continuous service with the company.
Spruce Biosciences' chief executive officer and director reported a stock option repricing involving 10,000 employee stock options. On December 11, 2025, 10,000 options with an exercise price of $344.25 per share were disposed of and 10,000 new employee stock options were acquired with an exercise price of $104.13 per share, all expiring on January 2, 2032.
The filing explains that this reflects a one-time option repricing effective December 11, 2025 for options with exercise prices of $106.09 per share or higher. The repriced options now carry an exercise price of $104.13 per share, equal to the thirty-day trailing volume-weighted average price of the common stock on the Nasdaq Capital Market on the repricing date. If an optionholder exercises a repriced option before completing a one-year retention period, they must pay the original higher exercise price, and vesting, expiration and share amounts remain unchanged.
Spruce Biosciences reported that a director updated several stock option grants on December 11, 2025. The disclosure describes a one-time option repricing that followed an earlier reverse stock split in which every seventy-five shares of common stock were combined into one share, and existing options and their exercise prices were adjusted accordingly.
Under the repricing, options with exercise prices of $106.09 per share or higher were amended so the exercise price is now $104.13 per share, equal to the 30-day trailing volume-weighted average price of the common stock on the Nasdaq Capital Market on the repricing date. For this director, fully vested stock option positions expiring between 2029 and 2033 were canceled and replaced one-for-one at the new price, leaving separate grants of 173, 309, 362, 133 and 400 options outstanding. Vesting schedules, expiration dates and share counts were unchanged, and any option exercised within a one-year retention period must still be paid at the original, higher exercise price.
Spruce Biosciences director reported an option repricing and prior reverse split effects. On December 11, 2025, the director reported the acquisition of 800 stock options with a new exercise price of $104.13 per share and the disposition of 800 options with a $169.50 exercise price, both expiring on May 24, 2033, as part of a one-time option repricing. Earlier, effective August 4, 2025, every seventy-five shares of common stock were combined into one share in a reverse stock split, and related option share counts and exercise prices were adjusted. The repriced options vest in equal monthly installments over three years from May 25, 2023, fully vest on the third anniversary, and vest in full upon a Change in Control under the equity plan, while early exercise within a roughly one-year retention period requires paying the original exercise price.
Spruce Biosciences reported a new stock option grant to a director. On 12/11/2025, the director acquired stock options to purchase 3,400 shares of common stock at an exercise price of $88.41, expiring on 12/10/2035. The options vest in equal monthly installments over three years so they are fully vested on the third anniversary of the grant date, and they will vest in full upon a Change in Control, subject to the director’s continuous service under the company’s 2020 Equity Incentive Plan.
Spruce Biosciences executive Samir Gharib, the company’s President and CFO, reported vesting of restricted stock units (RSUs) that converted into common shares. On December 10, 2025, 514 RSUs from a March 14, 2024 grant vested after a specified clinical development objective was achieved; 184 shares were withheld for taxes, resulting in a net issuance of 330 common shares. On December 11, 2025, 1,900 RSUs from a separate grant vested, with 680 shares withheld for taxes and a net issuance of 1,220 shares. Following these transactions, Gharib directly owns 7,616 shares of Spruce Biosciences common stock and 5,700 RSUs, each representing a right to receive one share.
Spruce Biosciences, Inc. reported insider equity activity by its chief executive officer and director involving restricted stock units (RSUs) that vested into common shares and related tax withholding. On December 10, 2025, 1,196 RSUs vested into common stock, and 428 shares were withheld for taxes at $85.67 per share, resulting in a net issuance of 768 shares. On December 11, 2025, 4,950 RSUs vested, and 2,194 shares were withheld for taxes at $88.41 per share, resulting in a net issuance of 2,756 shares.
Following these transactions, the reporting person directly owned 12,998 shares of Spruce Biosciences common stock and 14,850 RSUs. The RSUs include a 4,784-unit award tied to achievement of a specified clinical development objective, vesting in four annual 25% tranches, and a separate 19,800-unit award vesting 25% at grant and 25% on each of December 15, 2026, 2027 and 2028, subject to continued service.
Spruce Biosciences (SPRB) reported an insider equity event for its President and CFO, Samir Gharib. A performance-based award of 2,053 RSUs granted on March 14, 2024 vested on October 20, 2025 after the board certified performance goals. To cover taxes, 661 shares were withheld at $148.16, resulting in a net issuance of 1,392 shares.
Following these transactions, the officer beneficially owns 6,066 shares, held directly. Each RSU represents the right to receive one share of SPRB common stock upon vesting.
Spruce Biosciences (SPRB) reported an insider equity event by its Chief Executive Officer and director. On 10/20/2025, the Board certified performance goals, causing 4,784 performance‑based RSUs granted on March 14, 2024 to vest. Each RSU represents the right to receive one share of SPRB common stock.
In connection with the vesting, 1,539 shares were withheld for taxes at a price of $148.16, resulting in a net issuance of 3,245 shares. Following these transactions, the reporting person directly beneficially owned 9,474 shares. The Form 4 reflects an “M” code for settlement of RSUs into common stock at $0 and an “F” code for tax withholding.
Spruce Biosciences (SPRB) — Form 4 insider trading update. Parkman Healthcare Partners LLC and Gregory Martinez reported trades on 10/06/2025 as indirect owners. They purchased 256 shares of common stock at a weighted average price of $17.9108 (within $17.55–$18.00), then sold 232 shares at $19.3264 (within $19.125–$19.63) and sold 25 shares at $17.4557 (within $17.44–$17.56). Following the reported transactions, they beneficially owned 1,050 shares indirectly through private funds. Each reporting person disclaims beneficial ownership beyond pecuniary interest.
Insider transactions by Parkman Healthcare Partners LLC in Spruce Biosciences (SPRB) show net activity on 10/06/2025. The reporting entity acquired 256 shares of common stock at a weighted-average price of $17.9108 and disposed of 232 shares at a weighted-average $19.3264 plus 25 shares at a weighted-average $17.4557. After these trades the reported beneficial ownership counts are 1,307, 1,075, and 1,050 respectively for each reported line. The filing notes these holdings represent a pecuniary interest held through private funds and disclaims direct beneficial ownership except to the extent of that interest. A signed filing was submitted by Gregory Martinez as CIO on 10/08/2025.